Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31248558 | 1.00 | NR1H2 (0.43) | NR1H2HDAC1HDAC6PDE4BMAPK1 | |
| SCHEMBL30988665 | 1.00 | NR1H2 (0.43) | NR1H2HDAC1HDAC6PDE4BMAPK1 | |
| SCHEMBL31248547 | 1.00 | NR1H2 (0.43) | NR1H2HDAC1HDAC6PDE4BMAPK1 | |
| SCHEMBL31248557 | 0.87 | PDE4B (0.40) | NR1H2PDE4BMAPK1KMT2APKM | |
| SCHEMBL12520694 | 0.87 | ALDH1A1 (0.51) | PDE4BMAPK1KMT2AGPR119MAPT | |
| SCHEMBL6017253 | 0.86 | GPR119 (0.49) | PDE4BMAPK1KMT2AGPR119TP53 | |
| SCHEMBL26102356 | 0.86 | GPR119 (0.49) | PDE4BMAPK1KMT2AGPR119TP53 | |
| SCHEMBL16026535 | 0.86 | ESR2 (0.44) | PDE4BMAPK1KMT2AUSP30GPR119 | |
| SCHEMBL17519223 | 0.85 | RORC (0.44) | HDAC1PDE4BMAPK1KMT2AGPR119 | |
| SCHEMBL38661093 | 0.85 | MAPK1 (0.45) | PDE4BMAPK1USP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739667-A2 | INDOLE DERIVATIVES WITH FACTOR B INHIBITORY ACTIVITY | Sitala Bio Ltd (GB) | 2026-05-13 | — | — | EP | disclosed |
| CN-119330893-A | Resolution method of nitrogen heterocyclic derivative | 南京正大天晴制药有限公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2025008516-A2 | NOVEL COMPOUNDS | SITALA BIO LTD (GB) | 2025-01-09 | — | — | WO | disclosed |
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1358183-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| WO-2002088106-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | NR1H2 860/4885HDAC1 493/4885HDAC6 215/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | NR1H2 1544/4885HDAC1 524/4885HDAC6 162/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | NR1H2 937/4885HDAC1 343/4885HDAC6 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.